A phase III randomized trial of weight loss to reduce cancer-related fatigue among overweight and obese breast cancer patients: MEDEA Study design

Antonio Di Meglio, Elise Martin, Tracy E Crane, Cecile Charles, Aude Barbier, Bruno Raynard, Anthony Mangin, Olivier Tredan, Carole Bouleuc, Paul H Cottu, Laurence Vanlemmens, Carine Segura-Djezzar, Anne Lesur, Barbara Pistilli, Florence Joly, Thomas Ginsbourger, Bernadette Coquet, Iris Pauporte, Guillemette Jacob, Aude Sirven, Julia Bonastre, Jennifer A Ligibel, Stefan Michiels, Ines Vaz-Luis, Antonio Di Meglio, Elise Martin, Tracy E Crane, Cecile Charles, Aude Barbier, Bruno Raynard, Anthony Mangin, Olivier Tredan, Carole Bouleuc, Paul H Cottu, Laurence Vanlemmens, Carine Segura-Djezzar, Anne Lesur, Barbara Pistilli, Florence Joly, Thomas Ginsbourger, Bernadette Coquet, Iris Pauporte, Guillemette Jacob, Aude Sirven, Julia Bonastre, Jennifer A Ligibel, Stefan Michiels, Ines Vaz-Luis

Abstract

Background: Elevated body mass index (BMI) represents a risk factor for cancer-related fatigue (CRF). Weight loss interventions are feasible and safe in cancer survivors, leading to improved cardio-metabolic and quality of life (QOL) outcomes and modulating inflammatory biomarkers. Randomized data are lacking showing that a lifestyle intervention aimed at weight loss, combining improved diet, exercise, and motivational counseling, reduces CRF. Motivating to Exercise and Diet, and Educating to healthy behaviors After breast cancer (MEDEA) is a multi-center, randomized controlled trial evaluating the impact of weight loss on CRF in overweight or obese survivors of breast cancer. Herein, we described the MEDEA methodology.

Methods: Patients (N = 220) with stage I-III breast cancer and BMI ≥ 25 kg/m2, within 12 months of primary treatment, and able to walk ≥ 400 m are eligible to enroll. Participants are randomized 1:1 to health education alone vs. a personalized telephone-based weight loss intervention plus health education. Both arms receive a health education program focusing on healthy living. Patients in the intervention arm are paired with an individual lifestyle coach, who delivers the intervention through 24 semi-structured telephone calls over 1 year. Intervention goals include weight loss ≥ 10% of baseline, caloric restriction of 500-1000 Kcal/day, and increased physical activity (PA) to 150 (initial phase) and 225-300 min/week (maintenance phase). The intervention is based on the social cognitive theory and is adapted from the Breast Cancer Weight Loss trial (BWEL, A011401). The primary endpoint is the difference in self-reported CRF (EORTC QLQ-C30) between arms. Secondary endpoints include the following: QOL (EORTC QLQ-C30, -BR45, -FA12), anxiety, and depression (HADS); weight and BMI, dietary habits and quality, PA, and sleep; health care costs (hospital-admissions, all-drug consumption, sick leaves) and cost-effectiveness (cost per quality-adjusted life-year); and patient motivation and satisfaction. The primary analysis of MEDEA will compare self-reported CRF at 12 months post-randomization between arms, with 80.0% power (two-sided α = 0.05) to detect a standardized effect size of 0.40.

Discussion: MEDEA will test the impact of a weight loss intervention on CRF among overweight or obese BC survivors, potentially providing additional management strategies and contributing to establish weight loss support as a new standard of clinical care.

Trial registration: ClinicalTrials.gov NCT04304924.

Keywords: Body mass index; Breast cancer; Cancer-related fatigue; Obesity; Overweight; Survivorship; Weight loss.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
MEDEA Study design. BMI, body mass index
Fig. 2
Fig. 2
MEDEA Study schema and timeline. M, month

References

    1. Otto SJ, Fracheboud J, Verbeek ALM, Boer R, Reijerink-Verheij JC, Otten JD, Broeders MJ, de Koning HJ, National Evaluation Team for Breast Cancer Screening Mammography screening and risk of breast cancer death: a population-based case-control study. Cancer Epidemiol Biomarkers Prev. 2012;21(1):66–73. doi: 10.1158/1055-9965.EPI-11-0476.
    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492.
    1. Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, Cannady RS, Pratt-Chapman ML, Edge SB, Jacobs LA, Hurria A, Marks LB, LaMonte S, Warner E, Lyman GH, Ganz PA. American cancer society/American society of clinical oncology breast cancer survivorship care guideline. CA Cancer J Clin. 2016;66(1):43–73. doi: 10.3322/caac.21319.
    1. Denlinger CS, Sanft T, Baker KS, et al. Survivorship, version 2.2018: clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2018;16(10):1216–1247. doi: 10.6004/jnccn.2018.0078.
    1. Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, Morrow GR. Cancer-related fatigue: the scale of the problem. Oncologist. 2007;12(Suppl 1):4–10. doi: 10.1634/theoncologist.12-S1-4.
    1. Di Meglio A, Havas J, Soldato D, Presti D, Martin E, Pistilli B, Menvielle G, Dumas A, Charles C, Everhard S, Martin AL, Coutant C, Tarpin C, Vanlemmens L, Levy C, Rigal O, Delaloge S, Lin NU, Ganz PA, Partridge AH, André F, Michiels S, Vaz-Luis I. Development and validation of a predictive model of severe fatigue after breast cancer diagnosis: toward a personalized framework in survivorship care. J Clin Oncol. 2022:JCO2101252. 10.1200/JCO.21.01252. Epub ahead of print. PMID: 35061509.
    1. Bower JE, Ganz PA, Desmond KA, Bernaards C, Rowland JH, Meyerowitz BE, Belin TR. Fatigue in long-term breast carcinoma survivors. Cancer. 2006;106(4):751–758. doi: 10.1002/cncr.21671.
    1. Bower JE, Ganz PA, Desmond KA, Rowland JH, Meyerowitz BE, Belin TR. Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J Clin Oncol. 2000;18(4):743–753. doi: 10.1200/JCO.2000.18.4.743.
    1. Abrahams HJG, Gielissen MFM, Schmits IC, Verhagen CAHHVM, Rovers MM, Knoop H. Risk factors, prevalence, and course of severe fatigue after breast cancer treatment: a meta-analysis involving 12 327 breast cancer survivors. Ann Oncol. 2016;27(6):965–974. doi: 10.1093/annonc/mdw099.
    1. Poulson MJ. Not just tired. J Clin Oncol. 2001;19(21):4180–4181. doi: 10.1200/JCO.2001.19.21.4180.
    1. Andrykowski MA, Donovan KA, Laronga C, Jacobsen PB. Prevalence, predictors, and characteristics of off-treatment fatigue in breast cancer survivors. Cancer. 2010;116(24):5740–5748. doi: 10.1002/cncr.25294.
    1. Cella D, Lai JS, Chang C-HH, Peterman A, Slavin M. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer. 2002;94(2):528–538. doi: 10.1002/cncr.10245.
    1. Bower JE. Cancer-related fatigue—mechanisms, risk factors, and treatments. Nat Rev Clin Oncol. 2014;11(10):597–609. doi: 10.1038/nrclinonc.2014.127.
    1. Cella D, Davis K, Breitbart W, Curt G. Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol. 2001;19(14):3385–3391. doi: 10.1200/JCO.2001.19.14.3385.
    1. Minton O, Stone P. A systematic review of the scales used for the measurement of cancer-related fatigue (CRF) Ann Oncol. 2009;20(1):17–25. doi: 10.1093/annonc/mdn537.
    1. Curt GA, Breitbart W, Cella D, Groopman JE, Horning SJ, Itri LM, Johnson DH, Miaskowski C, Scherr SL, Portenoy RK, Vogelzang NJ. Impact of cancer-related fatigue on the lives of patients: new findings from the fatigue coalition. Oncologist. 2000;5(5):353–360. doi: 10.1634/theoncologist.5-5-353.
    1. Broeckel JA, Jacobsen PB, Horton J, Balducci L, Lyman GH. Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. J Clin Oncol. 1998;16(5):1689–1696. doi: 10.1200/JCO.1998.16.5.1689.
    1. Sparano JA, Wang M, Zhao F, Stearns V, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge GW, Jr, Wood WC, Fetting J, Davidson NE. Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer. 2012;118(23):5937–5946. doi: 10.1002/cncr.27527.
    1. Ligibel J. Lifestyle factors in cancer survivorship. J Clin Oncol. 2012;30(30):3697–3704. doi: 10.1200/JCO.2012.42.0638.
    1. Sestak I, Distler W, Forbes JF, Dowsett M, Howell A, Cuzick J. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol. 2010;28(21):3411–3415. doi: 10.1200/JCO.2009.27.2021.
    1. Irwin ML, McTiernan A, Baumgartner RN, Baumgartner KB, Bernstein L, Gilliland FD, Ballard-Barbash R. Changes in body fat and weight after a breast cancer diagnosis: influence of demographic, prognostic, and lifestyle factors. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(4):774–782. doi: 10.1200/JCO.2005.04.036.
    1. Makari-Judson G, Braun B, Jerry DJ, Mertens WC. Weight gain following breast cancer diagnosis: implication and proposed mechanisms. World J Clin Oncol. 2014;5(3):272–282. doi: 10.5306/wjco.v5.i3.272.
    1. .
    1. Donovan KA, Small BJ, Andrykowski MA, Munster P, Jacobsen PB. Utility of a cognitive-behavioral model to predict fatigue following breast cancer treatment. Health Psychol. 2007;26(4):464–472. doi: 10.1037/0278-6133.26.4.464.
    1. Reinertsen KV, Cvancarova M, Loge JH, Edvardsen H, Wist E, Fosså SD. Predictors and course of chronic fatigue in long-term breast cancer survivors. J Cancer Surviv. 2010;4(4):405–414. doi: 10.1007/s11764-010-0145-7.
    1. Paxton RJ, Phillips KL, Jones LA, Chang S, Taylor WC, Courneya KS, Pierce JP. Associations among physical activity, body mass index, and health-related quality of life by race/ethnicity in a diverse sample of breast cancer survivors. Cancer. 2012;118(16):4024–4031. doi: 10.1002/cncr.27389.
    1. Pierce JP, Natarajan L, Caan BJ, Parker BA, Greenberg ER, Flatt SW, Rock CL, Kealey S, al-Delaimy WK, Bardwell WA, Carlson RW, Emond JA, Faerber S, Gold EB, Hajek RA, Hollenbach K, Jones LA, Karanja N, Madlensky L, Marshall J, Newman VA, Ritenbaugh C, Thomson CA, Wasserman L, Stefanick ML. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women’s Healthy Eating and Living (WHEL) randomized trial. JAMA. 2007;298(3):289–298. doi: 10.1001/jama.298.3.289.
    1. Inglis JE, Janelsins MC, Culakova E, Mustian KM, Lin PJ, Kleckner IR, Peppone LJ. Longitudinal assessment of the impact of higher body mass index on cancer-related fatigue in patients with breast cancer receiving chemotherapy. Support Care Cancer. 2020;28(3):1411–1418. doi: 10.1007/s00520-019-04953-4.
    1. Inglis JE, Kleckner AS, Lin PJ, Gilmore NJ, Culakova E, VanderWoude AC, Mustian KM, Fernandez ID, Dunne RF, Deutsch J, Peppone LJ. Excess body weight and cancer-related fatigue, systemic inflammation, and serum lipids in breast cancer survivors. Nutr Cancer. 2021;73(9):1676–1686. doi: 10.1080/01635581.2020.1807574.
    1. .
    1. Bower JE, Bak K, Berger A, Breitbart W, Escalante CP, Ganz PA, Schnipper HH, Lacchetti C, Ligibel JA, Lyman GH, Ogaily MS, Pirl WF, Jacobsen PB, American Society of Clinical Oncology Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical Oncology Clinical Practice Guideline adaptation. J Clin Oncol. 2014;32(17):1840–1850. doi: 10.1200/JCO.2013.53.4495.
    1. Collado-Hidalgo A. Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin Cancer Res. 2006;12(9):2759–2766. doi: 10.1158/1078-0432.CCR-05-2398.
    1. Bower JE, Ganz PA, Irwin MR, Arevalo JMG, Cole SW. Fatigue and gene expression in human leukocytes: increased NF-κB and decreased glucocorticoid signaling in breast cancer survivors with persistent fatigue. Brain Behav Immun. 2011;25(1):147–150. doi: 10.1016/j.bbi.2010.09.010.
    1. Orre IJ, Reinertsen KV, Aukrust P, Dahl AA, Fosså SD, Ueland T, Murison R. Higher levels of fatigue are associated with higher CRP levels in disease-free breast cancer survivors. J Psychosom Res. 2011;71(3):136–141. doi: 10.1016/j.jpsychores.2011.04.003.
    1. Bower JE, Ganz PA, Tao ML, Hu W, Belin TR, Sepah S, Cole S, Aziz N. Inflammatory biomarkers and fatigue during radiation therapy for breast and prostate cancer. Clin Cancer Res. 2009;15(17):5534–5540. doi: 10.1158/1078-0432.CCR-08-2584.
    1. Geinitz H, Zimmermann FB, Stoll P, Thamm R, Kaffenberger W, Ansorg K, Keller M, Busch R, van Beuningen D, Molls M. Fatigue, serum cytokine levels, and blood cell counts during radiotherapy of patients with breast cancer. Int J Radiat Oncol. 2001;51(3):691–698. doi: 10.1016/S0360-3016(01)01657-1.
    1. Goodwin PJ, Stambolic V. Impact of the obesity epidemic on cancer. Annu Rev Med. 2015;66(1):281–296. doi: 10.1146/annurev-med-051613-012328.
    1. Goodwin P, Esplen MJ, Butler K, Winocur J, Pritchard K, Brazel S, Gao J, Miller A. Multidisciplinary weight management in locoregional breast cancer: results of a phase II study. Breast Cancer Res Treat. 1998;48(1):53–64. doi: 10.1023/A:1005942017626.
    1. Shaw C, Mortimer P, Judd PA. Randomized controlled trial comparing a low-fat diet with a weight-reduction diet in breast cancer-related lymphedema. Cancer. 2007;109(10):1949–1956. doi: 10.1002/cncr.22638.
    1. Thomson CA, Stopeck AT, Bea JW, et al. Changes in body weight and metabolic indexes in overweight breast cancer survivors enrolled in a randomized trial of low-fat vs. reduced carbohydrate diets. Nutr Cancer. 2010;62(8):1142–1152. doi: 10.1080/01635581.2010.513803.
    1. Befort CA, Klemp JR, Austin HL, Perri MG, Schmitz KH, Sullivan DK, Fabian CJ. Outcomes of a weight loss intervention among rural breast cancer survivors. Breast Cancer Res Treat. 2012;132(2):631–639. doi: 10.1007/s10549-011-1922-3.
    1. Mefferd K, Nichols JF, Pakiz B, Rock CL. A cognitive behavioral therapy intervention to promote weight loss improves body composition and blood lipid profiles among overweight breast cancer survivors. Breast Cancer Res. Treat. 2007;104(2):145–152. doi: 10.1007/s10549-006-9410-x.
    1. Sedlacek SM, Playdon MC, Wolfe P, McGinley JN, Wisthoff MR, Daeninck EA, Jiang W, Zhu Z, Thompson HJ. Effect of a low fat versus a low carbohydrate weight loss dietary intervention on biomarkers of long term survival in breast cancer patients (‘CHOICE’): study protocol. BMC Cancer. 2011;11(1):287. doi: 10.1186/1471-2407-11-287.
    1. Thompson HJ, Sedlacek SM, Paul D, et al. Effect of dietary patterns differing in carbohydrate and fat content on blood lipid and glucose profiles based on weight-loss success of breast-cancer survivors. Breast Cancer Res. 2012;14(1):R1. doi: 10.1186/bcr3082.
    1. Goodwin PJ, Segal RJ, Vallis M, Ligibel JA, Pond GR, Robidoux A, Blackburn GL, Findlay B, Gralow JR, Mukherjee S, Levine M, Pritchard KI. Randomized trial of a telephone-based weight loss intervention in postmenopausal women with breast cancer receiving letrozole: the LISA trial. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(21):2231–2239. doi: 10.1200/JCO.2013.53.1517.
    1. Rock CL, Flatt SW, Byers TE, Colditz GA, Demark-Wahnefried W, Ganz PA, Wolin KY, Elias A, Krontiras H, Liu J, Naughton M, Pakiz B, Parker BA, Sedjo RL, Wyatt H. Results of the Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) Trial: a behavioral weight loss intervention in overweight or obese breast cancer survivors. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(28):3169–3176. doi: 10.1200/JCO.2015.61.1095.
    1. Ligibel JA, Barry WT, Alfano C, Hershman DL, Irwin M, Neuhouser M, Thomson CA, Delahanty L, Frank E, Spears P, Paskett ED, Hopkins J, Bernstein V, Stearns V, White J, Hahn O, Hudis C, Winer EP, Wadden TA, Goodwin PJ. Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design. NPJ Breast Cancer. 2017;3(1):37. doi: 10.1038/s41523-017-0040-8.
    1. Ligibel JA, Barry WT, Alfano C, Hershman DL, Irwin M, Neuhouser M, et al. Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design. NPJ Breast Cancer. 2017;3(1):37. doi: 10.1038/s41523-017-0040-8.
    1. Chlebowski RT, Reeves MM. Weight loss randomized intervention trials in female cancer survivors. J Clin Oncol. 2016;34(35):4238–4248. doi: 10.1200/JCO.2016.69.4026.
    1. Di Meglio A, Michiels S, Jones LW, et al. Changes in weight, physical and psychosocial patient-reported outcomes among obese women receiving treatment for early-stage breast cancer: a nationwide clinical study. Breast. 2020;52:23–32. doi: 10.1016/j.breast.2020.04.002.
    1. Di Meglio A, Menvielle G, Dumas A, et al. Body weight and return to work among survivors of early-stage breast cancer. ESMO Open. 2020;5(6):e000908. doi: 10.1136/esmoopen-2020-000908.
    1. Rock CL, Byers TE, Colditz GA, Demark-Wahnefried W, Ganz PA, Wolin KY, Elias A, Krontiras H, Liu J, Naughton M, Pakiz B, Parker BA, Sedjo RL, Wyatt H, Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) Trial Group Reducing breast cancer recurrence with weight loss, a vanguard trial: the Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) Trial. Contemp Clin Trials. 2013;34(2):282–295. doi: 10.1016/j.cct.2012.12.003.
    1. Mary Dwyer N, Rashmi Kumar M, Swarm R, et al. Continue NCCN Guidelines Panel Disclosures NCCN Guidelines™ Version 2.2011 Panel Members Adult Cancer Pain. 2011.
    1. Riba MB, Donovan KA, et al. NCCN Guidelines Version 2.2021 Distress Management Continue NCCN Guidelines Panel Disclosures. 2021.
    1. Franzoi MA, Agostinetto E, Perachino M, et al. Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer. Lancet Oncol. 2021;22(7):e303–e313. doi: 10.1016/S1470-2045(20)30666-5.
    1. Demark-Wahnefried W, Schmitz KH, Alfano CM, Bail JR, Goodwin PJ, Thomson CA, Bradley DW, Courneya KS, Befort CA, Denlinger CS, Ligibel JA, Dietz WH, Stolley MR, Irwin ML, Bamman MM, Apovian CM, Pinto BM, Wolin KY, Ballard RM, Dannenberg AJ, Eakin EG, Longjohn MM, Raffa SD, Adams-Campbell LL, Buzaglo JS, Nass SJ, Massetti GM, Balogh EP, Kraft ES, Parekh AK, Sanghavi DM, Morris GS, Basen-Engquist K. Weight management and physical activity throughout the cancer care continuum. CA Cancer J Clin. 2018;68(1):64–89. doi: 10.3322/caac.21441.
    1. Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, Franzini L, Williams A, de Haes HC, Hopwood P, Cull A, Aaronson NK. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol. 1996;14(10):2756–2768. doi: 10.1200/JCO.1996.14.10.2756.
    1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, Haes JCJM, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–376. doi: 10.1093/jnci/85.5.365.
    1. .
    1. Esliger DW, Tremblay MS. Technical reliability assessment of three accelerometer models in a mechanical setup. Med Sci Sports Exerc. 2006;38(12):2173–2181. doi: 10.1249/01.mss.0000239394.55461.08.
    1. .
    1. Gazan R, Vieux F, Darmon N, Maillot M. Structural validation of a French food frequency questionnaire of 94 items. Front Nutr. 2017;4:62. doi: 10.3389/fnut.2017.00062.
    1. .
    1. .
    1. Puetz TW, Herring MP. Differential effects of exercise on cancer-related fatigue during and following treatment. Am J Prev Med. 2012;43(2):e1–e24. doi: 10.1016/j.amepre.2012.04.027.
    1. Brown JC, Huedo-Medina TB, Pescatello LS, Pescatello SM, Ferrer RA, Johnson BT. Efficacy of exercise interventions in modulating cancer-related fatigue among adult cancer survivors: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2011;20(1):123–133. doi: 10.1158/1055-9965.EPI-10-0988.
    1. Speck RM, Courneya KS, Mâsse LC, Duval S, Schmitz KH. An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. J Cancer Surviv. 2010;4(2):87–100. doi: 10.1007/s11764-009-0110-5.
    1. Cohen J. Statistical power analysis for the behavioral sciences. Routledge; 2013.
    1. .
    1. Bjelic-Radisic V, Cardoso F, Cameron D, Brain E, Kuljanic K, da Costa RA, Conroy T, Inwald EC, Serpentini S, Pinto M, Weis J, Morag O, Lindviksmoen Astrup G, Tomaszweksi KA, Pogoda K, Sinai P, Sprangers M, Aaronson N, Velikova G, Greimel E, Arraras J, Bottomley A, Bleiker E, Bliem B, Chie W, Creutzberg C, Deville V, Duhoux F, Eilf K, Hartup S, Koller M, Nagele E, Nicolatou-Galitis O, Oberguggenberger A, Schmalz C, Winters Z. An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45. Ann Oncol Off J Eur Soc Med Oncol. 2020;31(2):283–288. doi: 10.1016/j.annonc.2019.10.027.
    1. Rack B, Andergassen U, Neugebauer J, Salmen J, Hepp P, Sommer H, Lichtenegger W, Friese K, Beckmann MW, Hauner D, Hauner H, Janni W. The German SUCCESS C study - the first European lifestyle study on breast cancer. Breast Care. 2010;5(6):395–400. doi: 10.1159/000322677.
    1. Villarini A, Pasanisi P, Traina A, Mano MP, Bonanni B, Panico S, Scipioni C, Galasso R, Paduos A, Simeoni M, Bellotti E, Barbero M, Macellari G, Venturelli E, Raimondi M, Bruno E, Gargano G, Fornaciari G, Morelli D, Seregni E, Krogh V, Berrino F. Lifestyle and breast cancer recurrences: the DIANA-5 trial. Tumori. 2012;98(1):1–18. doi: 10.1700/1053.11494.
    1. .
    1. .
    1. Ligibel JA, Basen-Engquist K, Bea JW. Weight management and physical activity for breast cancer prevention and control. Am Soc Clin Oncol Educ B. 2019;39(39):e22–e33. doi: 10.1200/EDBK_237423.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi